GNLX:NASDAQ
Genelux Corp
2,54 US$
arrow_downward
-0,59%(-0,015) 1D
2,59 US$
arrow_upward
+1,77% (+0,045)todayPre-market
Closed: 12 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
2,59 US$
High
2,59 US$
Low
2,51 US$
Mkt. cap
115,15 მლნ.
Avg. vol.
260,79 ათ.
Volume
125,00
52-wk high
8,54 US$
52-wk low
2,29 US$
EPS
-0,87 US$
Beta
0,59
Shares outstanding
45,24 მლნ.
No. of employees
26
Open
2,59 US$
High
2,59 US$
Low
2,51 US$
Mkt. cap
115,15 მლნ.
Avg. vol.
260,79 ათ.
Volume
125,00
52-wk high
8,54 US$
52-wk low
2,29 US$
EPS
-0,87 US$
Beta
0,59
Shares outstanding
45,24 მლნ.
No. of employees
26
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 თვის წინ
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Consensus Miss Rate
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitegenelux.com